Satellos Bioscience Inc. (TSX:MSCL)
Canada · Delayed Price · Currency is CAD | Market Cap | 167.07M +45.8% |
| Revenue (ttm) | n/a |
| Net Income | -39.78M |
| EPS | -2.53 |
| Shares Out | 20.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,569 |
| Open | 8.10 |
| Previous Close | 8.02 |
| Day's Range | 8.00 - 8.27 |
| 52-Week Range | 6.24 - 18.98 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 15.33 (+91.63%) |
| Earnings Date | Aug 12, 2026 |
About Satellos Bioscience
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research ... [Read more]
Analyst Summary
According to 3 analysts, the average rating for MSCL stock is "Strong Buy." The 12-month stock price target is $15.33, which is an increase of 91.63% from the latest price.
News
Satellos Bioscience Annual report
Satellos Bioscience has published an annual report on June 3, 2026.
Satellos to Participate in Upcoming Investor Conferences
TORONTO, May 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines t...
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines t...
Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medic...
MSLE: Analyst Sets $11 Price Target for Satellos Bioscience
MSLE: Analyst Sets $11 Price Target for Satellos Bioscience
MSLE: HC Wainwright & Co. Raises Price Target for Satellos Bioscience | MSLE Stock News
MSLE: HC Wainwright & Co. Raises Price Target for Satellos Bioscience | MSLE Stock News
Satellos Bioscience: 2025 Financial Performance
Company Overview Satellos Bioscience Inc. (NASDAQ: MSLE) is a clinical-stage biotechnology company focused on developing SAT-3247 to treat degenerative muscle... The post Satellos Bioscience: 2025 Fin...
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker "MSLE" on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a place...
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“ Satellos ” or the “ Company ”), a clinical-stage biotechnology company developing life-improving medic...
Satellos Bioscience Inc. Common Stock trading resumes
10:09 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading resumes
Satellos Bioscience Inc. Common Stock trading halted, volatility trading pause
10:04 EDT Satellos (MSLE) Bioscience Inc. Common Stock trading halted, volatility trading pause
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos to Participate in Upcoming Investor Conferences
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regene...
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regene...
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos Bioscience Registration statement: Registration filing
Satellos Bioscience filed a registration statement on February 5, 2026, providing details about a securities offering with the SEC.
Satellos Bioscience appoints Antoinette Paone as chief development officer
Satellos Bioscience (MSCLF) announced the appointment of Antoinette Paone as chief development officer and head of regulatory affairs. Paone joins Satellos from Generation Bio (GBIO), where she most r...
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...
Satellos to Participate in December Investor Conferences
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenera...